Del Fattore A - Search Results

1

Dual PI3 K/mTOR inhibition reduces prostate cancer bone engraftment altering tumor-induced bone remodeling.

Mancini A, Colapietro A, Pompili S, Del Fattore A, Delle Monache S, Biordi LA, Angelucci A, Mattei V, Liang C, Gravina GL, Festuccia C. Mancini A, et al. Among authors: del fattore a. Tumour Biol. 2018 Apr;40(4):1010428318771773. doi: 10.1177/1010428318771773. Tumour Biol. 2018. PMID: 29687745 Free article.

2

Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy.

Rucci N, Recchia I, Angelucci A, Alamanou M, Del Fattore A, Fortunati D, Susa M, Fabbro D, Bologna M, Teti A. Rucci N, et al. Among authors: del fattore a. J Pharmacol Exp Ther. 2006 Jul;318(1):161-72. doi: 10.1124/jpet.106.102004. Epub 2006 Apr 20. J Pharmacol Exp Ther. 2006. PMID: 16627750

3

Bone-targeted doxorubicin-loaded nanoparticles as a tool for the treatment of skeletal metastases.

Salerno M, Cenni E, Fotia C, Avnet S, Granchi D, Castelli F, Micieli D, Pignatello R, Capulli M, Rucci N, Angelucci A, Del Fattore A, Teti A, Zini N, Giunti A, Baldini N. Salerno M, et al. Among authors: del fattore a. Curr Cancer Drug Targets. 2010 Nov;10(7):649-59. doi: 10.2174/156800910793605767. Curr Cancer Drug Targets. 2010. PMID: 20578992

4

Receptor activator of NF-kappaB ligand enhances breast cancer-induced osteolytic lesions through upregulation of extracellular matrix metalloproteinase inducer/CD147.

Rucci N, Millimaggi D, Mari M, Del Fattore A, Bologna M, Teti A, Angelucci A, Dolo V. Rucci N, et al. Among authors: del fattore a. Cancer Res. 2010 Aug 1;70(15):6150-60. doi: 10.1158/0008-5472.CAN-09-2758. Epub 2010 Jul 14. Cancer Res. 2010. PMID: 20631064

5

Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells.

Megiorni F, Gravina GL, Camero S, Ceccarelli S, Del Fattore A, Desiderio V, Papaccio F, McDowell HP, Shukla R, Pizzuti A, Beirinckx F, Pujuguet P, Saniere L, der Aar EV, Maggio R, De Felice F, Marchese C, Dominici C, Tombolini V, Festuccia C, Marampon F. Megiorni F, et al. Among authors: del fattore a. J Hematol Oncol. 2017 Oct 6;10(1):161. doi: 10.1186/s13045-017-0530-z. J Hematol Oncol. 2017. PMID: 28985758 Free PMC article.

6

Testosterone-mediated activation of androgenic signalling sustains in vitro the transformed and radioresistant phenotype of rhabdomyosarcoma cell lines.

Giannattasio S, Megiorni F, Di Nisio V, Del Fattore A, Fontanella R, Camero S, Antinozzi C, Festuccia C, Gravina GL, Cecconi S, Dominici C, Di Luigi L, Ciccarelli C, De Cesaris P, Riccioli A, Zani BM, Lenzi A, Pestell RG, Filippini A, Crescioli C, Tombolini V, Marampon F. Giannattasio S, et al. Among authors: del fattore a. J Endocrinol Invest. 2019 Feb;42(2):183-197. doi: 10.1007/s40618-018-0900-6. Epub 2018 May 22. J Endocrinol Invest. 2019. PMID: 29790086

7

Disruption of MEK/ERK/c-Myc signaling radiosensitizes prostate cancer cells in vitro and in vivo.

Ciccarelli C, Di Rocco A, Gravina GL, Mauro A, Festuccia C, Del Fattore A, Berardinelli P, De Felice F, Musio D, Bouché M, Tombolini V, Zani BM, Marampon F. Ciccarelli C, et al. Among authors: del fattore a. J Cancer Res Clin Oncol. 2018 Sep;144(9):1685-1699. doi: 10.1007/s00432-018-2696-3. Epub 2018 Jun 29. J Cancer Res Clin Oncol. 2018. PMID: 29959569

8

NRF2 orchestrates the redox regulation induced by radiation therapy, sustaining embryonal and alveolar rhabdomyosarcoma cells radioresistance.

Marampon F, Codenotti S, Megiorni F, Del Fattore A, Camero S, Gravina GL, Festuccia C, Musio D, De Felice F, Nardone V, Santoro AN, Dominici C, Fanzani A, Pirtoli L, Fioravanti A, Tombolini V, Cheleschi S, Tini P. Marampon F, et al. Among authors: del fattore a. J Cancer Res Clin Oncol. 2019 Apr;145(4):881-893. doi: 10.1007/s00432-019-02851-0. Epub 2019 Jan 30. J Cancer Res Clin Oncol. 2019. PMID: 30701326

9

Pro-differentiating and radiosensitizing effects of inhibiting HDACs by PXD-101 (Belinostat) in in vitro and in vivo models of human rhabdomyosarcoma cell lines.

Marampon F, Di Nisio V, Pietrantoni I, Petragnano F, Fasciani I, Scicchitano BM, Ciccarelli C, Gravina GL, Festuccia C, Del Fattore A, Tombolini M, De Felice F, Musio D, Cecconi S, Tini P, Maddalo M, Codenotti S, Fanzani A, Polimeni A, Maggio R, Tombolini V. Marampon F, et al. Among authors: del fattore a. Cancer Lett. 2019 Oct 1;461:90-101. doi: 10.1016/j.canlet.2019.07.009. Epub 2019 Jul 17. Cancer Lett. 2019. PMID: 31325529

10

Dual CXCR4 and E-Selectin Inhibitor, GMI-1359, Shows Anti-Bone Metastatic Effects and Synergizes with Docetaxel in Prostate Cancer Cell Intraosseous Growth.

Festuccia C, Mancini A, Gravina GL, Colapietro A, Vetuschi A, Pompili S, Ventura L, Delle Monache S, Iorio R, Del Fattore A, Fogler W, Magnani J. Festuccia C, et al. Among authors: del fattore a. Cells. 2019 Dec 20;9(1):32. doi: 10.3390/cells9010032. Cells. 2019. PMID: 31877673 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

78 results

Search Page